BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sapanisertib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sapanisertib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02503722-9075@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sapanisertib: Phase 1 readout est. (NCT02503722)
DESCRIPTION:Sapanisertib\, phase 1.\nStudy: Testing the Combination of MLN0
 128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Recept
 or) Mutation Positive Non-small Cell Lung Cancer\nEstimated primary comple
 tion: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sapanisertib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT02503722
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385496-9075@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sapanisertib: Phase 2 readout est. (NCT06385496)
DESCRIPTION:Sapanisertib\, phase 2.\nStudy: Testing MLN0128 (TAK-228) as Po
 tentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH -
  Subprotocol L)\nEstimated primary completion: 30 June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sapanisertib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06385496
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06390865-9075@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sapanisertib: Phase 2 readout est. (NCT06390865)
DESCRIPTION:Sapanisertib\, phase 2.\nStudy: Testing MLN0128 (TAK-228) as Po
 tentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes 
 (MATCH - Subprotocol M)\nEstimated primary completion: 30 June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/sapanisertib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06390865
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06811116-9075@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sapanisertib: Phase 1/2 readout est. (NCT06811116)
DESCRIPTION:Sapanisertib\, phase 1/2.\nStudy: Testing the Addition of an An
 ti-cancer Drug\, Sapanisertib\, to the Usual Chemotherapy Treatment (Caboz
 antinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Pr
 otein β-Catenin\, The SAPHIRE Trial\nEstimated primary completion: 31 Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sapaniserti
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 811116
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-9075@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sapanisertib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Sapanisertib\, phase 2\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Targeted Therapy Directed by Genetic Testing in Treating Patients Wi
 th Advanced Refractory Solid Tumors\, Lymphomas\, or Multiple Myeloma (The
  MATCH Screening Trial)\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sapanisertib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463028-9075@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Sapanisertib: Phase 2 readout est. (NCT06463028)
DESCRIPTION:Sapanisertib\, phase 2.\nStudy: Sapanisertib and Serabelisib (P
 IKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in 
 Patients With Advanced/Recurrent Endometrial Cancer\nEstimated primary com
 pletion: September 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sapanisertib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06463028
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07558733-9075@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Sapanisertib: Phase 1/2 readout est. (NCT07558733)
DESCRIPTION:Sapanisertib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in P
 atients With HR+/HER2- Advanced/Metastatic Breast Cancer\nEstimated primar
 y completion: May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sapanisertib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07558733
URL:https://assetmemo.bio/drug/sapanisertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
